1. Scrip
  2. >>Business
  3. >>Deals

Patient-Centric: Evotec’s CSO Explains R&D Strategy

Says Patient-Driven Data Is Key For Precision Medicine

 
• By Sten Stovall

Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.

Patient_Data
Its two latest R&D alliances underline Evotec’s data-focused strategy. • Source: Shutterstock

Evotec SE has again stressed its view that patient-driven data are the future for innovation, most recently by inking an R&D pact with Centogene in Gaucher’s disease, two days after the German drug discovery and development company entered a new alliance with Novo Nordisk A/S in chronic kidney disease. Its chief science officer Cord Dohrmann told Scrip that more, similarly structured collaborations can be expected.

The mining and use of patient datasets “increasingly underpins” Evotec’s quest for developing precision medicine, the CSO said. “To achieve...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Nanobiotix/J&J Early Melanoma Data Show Potential For Future Indication

 
• By Mandy Jackson

Radiotherapy enhancer JNJ-1900 (NBTXR3) generated a 47% ORR and 78.9% DCR in melanoma patients after multiple prior rounds of treatment. Discussions about development in additional cancers are ongoing with partner J&J.

Roche Makes Major MASH Bid, Offering $2.4bn For 89Bio

 
• By Joseph Haas

About four months after GSK paid $1.2bn up front for another FGF21 analog in MASH, Roche looks to buy 89Bio, adding Phase III pegozafermin to its growing cardiometabolic pipeline.

Vepdegestrant Up For Grabs As Pfizer And Arvinas Step Aside

 
• By Manas Mishra

Pfizer and Arvinas have agreed to out-license their PROTAC breast cancer candidate, vepdegestrant, with Arvinas cutting jobs and refocusing on early-stage assets.

Publisher’s Spotlight: Shortlist Unveiled For Citeline Japan Awards

 
• By Ian Haydock

Shortlists of potential winners in all categories of the Citeline Japan Awards 2025 have now been released. Join us at the event in Tokyo on October 21, it’s not too late to book your table!

More from Business

Publisher’s Spotlight: Shortlist Unveiled For Citeline Japan Awards

 
• By Ian Haydock

Shortlists of potential winners in all categories of the Citeline Japan Awards 2025 have now been released. Join us at the event in Tokyo on October 21, it’s not too late to book your table!

Asia Deal Watch: Aditum Founds Kalexo With Mabwell To Develop Dual-Target SiRNA Asset

 
• By Joseph Haas, Xu Hu, Anju Ghangurde, Vibha Ravi, and Lisa Takagi

Plus deals involving Adagene/Exelixis, Biocytogen/Tubulis, Kwangdong/Ocugen, Dr. Reddy’s/J&J, Zydus/Synthon, Stallergenes/Nuance, Argo/Novartis, XW Pharma/Avadel, Biocytogen/Merck & Co., JCR/Medipal, Novatim/Radiance and more.

Roivant Sets The Stage For Commercial Return With Brepocitinib Data

 
• By Jessica Merrill

Positive Phase III data positions Roivant to launch the oral TYK2/JAK1 inhibitor for dermatomyositis, with an NDA filing planned in early 2026.